Tirzepatide locks in the global "King of Drugs" title with $36.5 billion; Eli Lilly expects revenue to exceed $80 billion this year

Gelonghui, February 5th｜The annual revenue of Eli Lilly's tirzepatide in 2025 will surpass Novo Nordisk's semaglutide, securing the global "King of Drugs" title for 2025 in advance. On February 4th local time, Eli Lilly (LLY.US) released its financial report for the fourth quarter of 2025 as well as the full year of 2025. The company's fourth-quarter revenue reached $19.29 billions, a year-on-year increase of 43%, exceeding analysts' expectations; total annual revenue reached $65.179 billions, a year-on-year increase of 44% at constant exchange rates (CER), and net profit was $20.64 billions, a year-on-year increase of 95%.